ALXO - ALX Oncology Short-Term Debt to Capital

Symbol and logo of brand ALX Oncology (ALXO)

ALX Oncology Holdings (ALXO) retains leading immunologists through attractive stock options and a robust scientific foundation, eliminating the loss of key personnel. The business relies on optimized medical component supply chains for the creation of anti-tumor proteins, ensuring high profitability. Share price fluctuations reaching 0.01 reflect the dynamics of a recognized expert in checkpoint inhibitors whose developments are highly valued in oncology.

Current Liabilities to Capital: ALX Oncology Holdings (ALXO) for 07/04/2022 - 11/01/2026

Summary analytical data breakdowns for ALX Oncology Holdings Inc. (ALXO)

- stock value and consensus price forecast:
Price Chart ALX Oncology|ALXO - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization ALX Oncology Holdings Inc.|ALXO - Real Price to Acquire Entire Company
- book capitalization information:
Net Assets per Single Share ALX Oncology|ALXO - Total Stockholders' Equity|Market Value to Book Value Ratio alxoncology.com|ALXO - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity ALX Oncology Holdings|ALXO - Long-Term Liabilities to Capital|Short-Term Debt to Capital ALX Oncology Holdings|ALXO - Company Total Indebtedness|Debt to Book Value ALX Oncology Holdings Inc.|ALXO - Long-Term Debt|Company Current Liabilities ALX Oncology|Quick Ratio alxoncology.com
- company profitability and valuation multiples indicators:
ALXO - Net Financial Result
Initial company analysis:ALX Oncology ALXO
Signature product of ALX Oncology Holdings Inc.

Disciplined capital management and the scientific expertise of ALX Oncology Holdings (ALXO) leadership minimize liquidity risks during the development of anti-cancer drugs. Analyzing the ratio of loans under one year to equity allows for an assessment of the company's dependence on short-term liabilities relative to its own equity; a decrease in this metric confirms financial stability, whereas a sharp increase signals a potential cash gap and the risk of a price decline.

Competitors of ALX Oncology Holdings (ALXO)

Short-Term Debt to Equity ImmunityBio Corp (IBRX)|Immunocore Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital JANX (Janux Therapeutics)|RCUS - Short-Term Debt to Equity Ratio|ZYME - Short-Term Debt to Equity|Current Liabilities to Capital Tango Therapeutics Inc|Iovance (IOVA) - Short-Term Debt to Equity|IMTX (Immatics Biotechnologies) - Short-Term Debt to Equity|Short-Term Debt to Equity Xencor, Inc.|Current Liabilities to Capital compasstherapeutics.com CMPX|Short-Term Debt to Capital REPL|Lyell (LYEL) - Short-Term Indebtedness to Equity|Innate Pharma, S.A. - Short-Term Debt to Equity Ratio|Pyxis Oncology Inc. (PYXS) - Current Liabilities to Capital|CGEN: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital IOBT (iobiotech.com)|STRO: Short-Term Debt to Capital|INKT - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Werewolf Therapeutics Inc.|Short-Term Debt to Equity Ratio Immix (IMMX)|Short-Term Debt to Equity Cue Biopharma (CUE)|Short-Term Debt to Equity Ratio pdsbiotech.com PDSB|Sonnet BioTherapeutics Holdings - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital MAIA Biotech MAIA|LIMN - Short-Term Debt to Equity|LVTX (LAVA Therapeutics N.V.) - Short-Term Debt to Capital Ratio|NextCure, Inc. (NXTC) - Short-Term Debt to Equity|Current Liabilities to Capital Leap Therapeutics (LPTX)|Short-Term Debt to Equity Ratio INTS|SNSE - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio TOVX (Synthetic Biologics)|Short-Term Loans to Capital Ratio GRTS|Short-Term Debt to Capital KA (Kineta, Inc.)|Ratio of Short-Term Indebtedness to Capital NEXI|Turnstone Biologics Corporation - Short-Term Debt to Capital|Current Liabilities to Capital Vaccinex Inc.|Harpoon Tx (HARP) - Short-Term Debt to Equity